Company analysts see stocks like Jefferies and Cigna leading the gains in the S&P 500 for this next stretch and see biopharmaceutical company Nektar Therapeutics doubling in the next 12 months.
Based on the difference between the bottom-up target price and the current trading level, Nektar is set to have 110% upside in the next 12 months. Industry analysts are also particularly bullish on medical implant manufacturer Abiomed, and oil and natural gas company Diamondback Energy.
On the other end of the spectrum, semiconductor company Advanced Micro Devices, asset manager Franklin Resources, Chipotle Mexican Grill, semiconductor manufacturer Xilinx, and lab and software company Waters Corp. are set to have double-digit losses.
To be sure, Wall Street has not always been accurate in predicting the future value of the market. In fact, these individual company analysts tend to be overly optimistic. Over the past five years, the S&P 500 has ended up 1.5% lower than their forecast. Over the past 15 years, the index has been almost 10% below Wall Street’s target.